No Data
No Data
List of Unrivaled Stocks (Part 1) [Ichimoku Equilibrium Chart/Kumoku Stock List]
○Kumojo Stock List Market Code Stock Name Closing Price Advance Span A Advance Span B Tokyo Stock Exchange Prime <1803> Shimizu Ken 961 941.5 953 <1812> Kashima 3010 2966.25 2751 <1835> Totekko 3135 3027.5 3088 <1893>
Convertible Stock List (Part 2) [Parabolic Signal Convertible Stock List]
○ List of sales conversion stocks market code stock name closing price SAR Tokyo Stock Exchange Prime <1333> Maruha Nichiro 2969 3106 <1429> Japan Aqua 964 1059 <1766> Token Corpo 10380 10860 <1815> Tetsuken 2641 2800 <1820> Nishimatsu Ken
Asahi Intec, SCSK, etc. (additional) Rating
Upgrade-Bullish Code | Stock Name | Securities Company | Conventional | After Change |------|--------------|--------------|--------------|<6594>|Nidec | Macquarie | “Neutral” | “Out P” |<6755>|Futtsu Zene |GS | “Selling”
Kewpie, Monotaro, etc. (added) Rating
Upgrade-Bullish Code | Stock Name | Securities Company | Conventional | After Change |------|------------|------------|------------|------------|<7599>|IDOM | Yamato | “3” | “2” |<7733>|Olympus |GS | “Neutral” | “Buy” |<7741>|HOYA
Astellas Pharmaceuticals, 24/3 revised downward operating profit 13 billion yen ← 83 billion yen
Astellas Pharmaceuticals <4503> announced revisions to its earnings forecast for the fiscal year ending 2024/3. Operating profit was revised downward from 83 billion yen to 13 billion yen. As a result of reviewing the asset value of the gene therapy program AT808, which is undergoing research and development for Friedreich ataxia patients, impairment losses of approximately 40 billion yen of intangible assets related to AT808 will be recorded as other expenses. [Positive Evaluation] <8233>Takashimaya Full Year | <6432>Takeuchi Production
Express News | Osaka Organic Chemical Industry - to Tender All of Its Stake in JSR Corp, Worth 706 Mln Yen, in Response to Jic-Led Tender Offer
No Data